AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

BOTANIX PHARMACEUTICALS LTD

0.150

+0.0053.45%

Volume:4.31M

Turnover:639.12K

Market Cap:294.17M

PE:-6.45

High:0.150

Open:0.145

Low:0.145

Close:0.145

52wk High:0.535

52wk Low:0.130

Shares:1.96B

Float Shares:1.72B

Volume Ratio:0.52

T/O Rate:0.25%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.023

EPS(LYR):-0.009

ROE:-56.99%

ROA:-34.36%

PB:3.18

PE(LYR):-16.24

Loading ...

Overview Company News Filings

ASX Penny Stocks: Botanix Pharmaceuticals And 2 Other Promising Picks

Simply Wall St.

Botanix's Six-Month Sales of Topical Gel Miss Expectations, Euroz Says

MT Newswires Live

Botanix Sofdra Launch Update Presentation - Correction-BOT.AX

BRIEF-Botanix Pharmaceuticals Ltd Says Sofdra Gross Sales Reach A$25 Million Since January

ASX ALERT-Botanix Provides Sofdra Launch Update-BOT.AX

Botanix Webinar Tuesday 8 July 2025 Registration Information-BOT.AX

Application for quotation of securities - BOT-BOT.AX

Botanix Pharmaceuticals Ltd. Announces FDA Approval of Sofpironium Topical Gel, Featured in JAAD Publication

Becoming a substantial holder-BOT.AX

Botanix Pharmaceuticals Enters into $30 Million Loan Facility; Shares Jump 7%

MT Newswires Live

Commercial, Development-Stage Biotechs Expected to See Little Impact from US Drug Pricing Order, Euroz Hartleys Says

MT Newswires Live

Botanix Pharmaceuticals Not Expected to be Impacted by Trump's Executive Orders, Euroz Hartleys Says

MT Newswires Live

Euroz Hartleys Maintains $0.80 Target for Botanix Pharmaceuticals; Trump's Drug Pricing Order Seen as Minimal Impact

Why is this ASX 300 stock crashing 18% today?

Botanix Says Unlikely to be Impacted by Proposed US Drug Pricing Policy Order

MT Newswires Live

ASX Midday Sector Update: Healthcare Sector Jumps, Information Technology Stocks Struggle

MT Newswires Live

Botanix Pharmaceuticals Seeks AU$40 Million via Institutional Placement; Shares Rise 10%

MT Newswires Live

BRIEF-Botanix Pharmaceuticals Says Received Firm Commitments For A$40 Million

BRIEF-Botanix Pharmaceuticals Seeks Trading Halt

3 reasons to buy this surging ASX All Ords healthcare share today

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BOT.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BOT.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"BOT.AU\",,,,,undefined,":{"symbol":"BOT.AU","market":"AU","secType":"STK","nameCN":"BOTANIX PHARMACEUTICALS LTD","latestPrice":0.15,"timestamp":1754633520000,"preClose":0.145,"halted":0,"volume":4312465,"delay":0,"nameEN":"BOTANIX PHARMACEUTICALS LTD","floatShares":1717605114,"shares":1961126643,"eps":-0.023239,"marketStatus":"Market Closed","change":0.005,"latestTime":"08-08 16:12:00 AEST","open":0.145,"high":0.15,"low":0.145,"amount":639116,"amplitude":0.034483,"askPrice":0.15,"askSize":1028787,"bidPrice":0.145,"bidSize":2083192,"shortable":3,"etf":0,"ttmEps":-0.023239,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1754870400000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.145,"openAndCloseTimeList":[[1754611200000,1754632800000]],"volumeRatio":0.5164499970142881,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"BOT.AU\",,,,,undefined,":{"symbol":"BOT.AU","floatShares":1717605114,"roa":"-34.36%","roe":"-56.99%","lyrEps":-0.009236,"volumeRatio":0.5164499970142881,"shares":1961126643,"dividePrice":0,"high":0.15,"amplitude":0.034483,"preClose":0.145,"low":0.145,"week52Low":0.13,"pbRate":"3.18","psRate":"142.17","week52High":0.535,"institutionHeld":0,"latestPrice":0.15,"committee":0.338821,"eps":-0.023239,"divideRate":0,"volume":4312465,"delay":0,"ttmEps":-0.023239,"open":0.145,"prevYearClose":0.435,"prevWeekClose":0.145,"prevMonthClose":0.15,"prevQuarterClose":0.32,"fiveDayClose":0.145,"twentyDayClose":0.155,"sixtyDayClose":0.38},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BOT.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BOT.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BOT.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2554402728","title":"ASX Penny Stocks: Botanix Pharmaceuticals And 2 Other Promising Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2554402728","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554402728?lang=en_us&edition=fundamental","pubTime":"2025-07-28 10:04","pubTimestamp":1753668292,"startTime":"0","endTime":"0","summary":"Australian shares are showing resilience as they head into Week 31 with a slight uptick, buoyed by a significant trade deal between the U.S. and European Union that promises to bring stability to global markets. In such an environment, investors often look for stocks that can offer growth potential without excessive risk, which is where penny stocks come into play. Although the term \"penny stocks\" might seem outdated, these smaller or newer companies continue to present unique opportunities...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-dxb/dimerix-shares/news/asx-penny-stocks-botanix-pharmaceuticals-and-2-other-promisi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IGL.AU","BK7048","XAO.AU","BK7129","BK7055","BK7058","GTN.AU","NGI.AU","BOT.AU","EZZ.AU","RPL.AU","CIA.AU","BK7501","AAL.AU","BK7104","BK7045","SXE.AU","DXB.AU","BK7067","WAF.AU","BK7502","BK7062","BK7506","BK7096","XJO.AU","BK7077","BK7508","BK7007","CLX.AU","XKO.AU","AHC.AU"],"gpt_icon":0},{"id":"2550369711","title":"Botanix's Six-Month Sales of Topical Gel Miss Expectations, Euroz Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2550369711","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550369711?lang=en_us&edition=fundamental","pubTime":"2025-07-10 13:57","pubTimestamp":1752127061,"startTime":"0","endTime":"0","summary":"Botanix Pharmaceuticals  gross sales of about AU$25 million from January through June for its Sofdra topical gel for excessive underarm sweating, missed expectations, and is a \"very disappointing\" outcome, according to a Thursday report by Euroz Hartleys.Net revenue came in at AU$5 million, well below Euroz's AU$14.8 million estimate and AU$8.8 million market consensus, due to weaker script volumes and net pricing.Despite the miss, key launch metrics were encouraging, with strong refill rates, rising prescriber numbers, and high adherence, Euroz said.The company's 70% share price drop appears overdone, with the market pricing in minimal Sofdra success, Euroz added.Euroz maintained Botanix's buy rating but lowered its price target to AU$0.40 from AU$0.80.Shares of the company fell 4% on market close.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BOT.AU"],"gpt_icon":0},{"id":"2550577427","title":"Botanix Sofdra Launch Update Presentation - Correction-BOT.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2550577427","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550577427?lang=en_us&edition=fundamental","pubTime":"2025-07-09 09:07","pubTimestamp":1752023227,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250709:nASX5ty5Bc","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250709:nASXbyxSh6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BOT.AU","BK7096","BK7502"],"gpt_icon":0},{"id":"2549563096","title":"BRIEF-Botanix Pharmaceuticals Ltd Says Sofdra Gross Sales Reach A$25 Million Since January","url":"https://stock-news.laohu8.com/highlight/detail?id=2549563096","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549563096?lang=en_us&edition=fundamental","pubTime":"2025-07-08 06:36","pubTimestamp":1751927816,"startTime":"0","endTime":"0","summary":"BRIEF-Botanix Pharmaceuticals Ltd Says Sofdra Gross Sales Reach A$25 Million Since JanuaryJuly 8 (Reuters) - Botanix Pharmaceuticals Ltd BOT.AX:SOFDRA GROSS SALES REACH A$25 MILLION SINCE JANUARYFurther company coverage: BOT.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250707:nFWN3T40N8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BOT.AU"],"gpt_icon":0},{"id":"2549565632","title":"ASX ALERT-Botanix Provides Sofdra Launch Update-BOT.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2549565632","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549565632?lang=en_us&edition=fundamental","pubTime":"2025-07-08 06:27","pubTimestamp":1751927250,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250707:nASX5f4N1W","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250707:nASX55CXvn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","BK7508","BOT.AU","BK7502"],"gpt_icon":0},{"id":"2548031353","title":"Botanix Webinar Tuesday 8 July 2025 Registration Information-BOT.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2548031353","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548031353?lang=en_us&edition=fundamental","pubTime":"2025-07-04 11:33","pubTimestamp":1751600019,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250704:nASX1ryjFs","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250704:nASX3bH3vj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7502","BOT.AU","BK7096"],"gpt_icon":0},{"id":"2547906069","title":"Application for quotation of securities - BOT-BOT.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2547906069","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547906069?lang=en_us&edition=fundamental","pubTime":"2025-06-30 17:49","pubTimestamp":1751276944,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250630:nASX20j8qY","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nASX5qwLDK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","BK7508","BOT.AU","BK7502"],"gpt_icon":0},{"id":"2547903637","title":"Botanix Pharmaceuticals Ltd. Announces FDA Approval of Sofpironium Topical Gel, Featured in JAAD Publication","url":"https://stock-news.laohu8.com/highlight/detail?id=2547903637","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547903637?lang=en_us&edition=fundamental","pubTime":"2025-06-30 08:38","pubTimestamp":1751243898,"startTime":"0","endTime":"0","summary":"Botanix Pharmaceuticals Ltd. has announced that their sofpironium topical gel, marketed under the brand name Sofdra, has been featured in the July 2025 issue of the Journal of the American Academy of Dermatology . The publication highlights the pooled efficacy and safety results from two phase 3 randomized, controlled, double-blind studies, which were pivotal in securing US Food and Drug Administration approval for Sofdra. This marks a significant regulatory achievement for Botanix Pharmaceuticals Ltd.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Botanix Pharmaceuticals Ltd. published the original content used to generate this news brief on June 30, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nNDLl3Vlz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BOT.AU","BK7096","BK7502","BK7508"],"gpt_icon":0},{"id":"2546791352","title":"Becoming a substantial holder-BOT.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2546791352","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546791352?lang=en_us&edition=fundamental","pubTime":"2025-06-27 14:55","pubTimestamp":1751007342,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250627:nASXYFQCJ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250627:nASX8yTMTr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7502","BK7508","BK7096","BOT.AU"],"gpt_icon":0},{"id":"2542322352","title":"Botanix Pharmaceuticals Enters into $30 Million Loan Facility; Shares Jump 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2542322352","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542322352?lang=en_us&edition=fundamental","pubTime":"2025-06-10 09:41","pubTimestamp":1749519710,"startTime":"0","endTime":"0","summary":"Botanix Pharmaceuticals (ASX:BOT) and its wholly-owned unit Botanix Pharmaceuticals entered into documentation with Kreos Capital VII (UK) and its related entities for a loan facility of up to the eur","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BOT.AU","BK4205","BK4528","BK7502","UK","BK7508","BK7096","BK4233"],"gpt_icon":0},{"id":"2535060550","title":"Commercial, Development-Stage Biotechs Expected to See Little Impact from US Drug Pricing Order, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2535060550","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535060550?lang=en_us&edition=fundamental","pubTime":"2025-05-14 13:35","pubTimestamp":1747200923,"startTime":"0","endTime":"0","summary":"Commercial and development-stage biotechnology companies are expected to face minimal to no impact from the recent US executive order aimed at lowering drug prices, according to a Wednesday note by Eu","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CYP.AU","SSI","BK7502","BK7096","SNT.AU","BK7508","BK7501","AGN.AU","BK7067","DXB.AU","BOT.AU"],"gpt_icon":0},{"id":"2535764277","title":"Botanix Pharmaceuticals Not Expected to be Impacted by Trump's Executive Orders, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2535764277","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535764277?lang=en_us&edition=fundamental","pubTime":"2025-05-13 12:56","pubTimestamp":1747112217,"startTime":"0","endTime":"0","summary":"Botanix Pharmaceuticals (ASX:BOT) is currently expected to have little to no impact from the executive order by Trump to lower drug prices in the US, Euroz Hartley said in a Tuesday note.The research ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BOT.AU","BK7096","BK7502"],"gpt_icon":0},{"id":"2535761899","title":"Euroz Hartleys Maintains $0.80 Target for Botanix Pharmaceuticals; Trump's Drug Pricing Order Seen as Minimal Impact","url":"https://stock-news.laohu8.com/highlight/detail?id=2535761899","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535761899?lang=en_us&edition=fundamental","pubTime":"2025-05-13 12:26","pubTimestamp":1747110360,"startTime":"0","endTime":"0","summary":"Euroz Hartleys has released a research note on Botanix Pharmaceuticals Ltd., maintaining a price target of $0.80. The report also mentions that President Trump's recent executive order on drug pricing will have \"little to no impact\" on Botanix or its product Sofdra. More details can be found at https://bit.ly/BOT-AnalystNote-May2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Botanix Pharmaceuticals Ltd. published the original content used to generate this news brief on May 13, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nNDL8Xm2p0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BOT.AU","BK7502","BK7508","BK7096"],"gpt_icon":0},{"id":"2534291338","title":"Why is this ASX 300 stock crashing 18% today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2534291338","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534291338?lang=en_us&edition=fundamental","pubTime":"2025-05-12 11:53","pubTimestamp":1747022011,"startTime":"0","endTime":"0","summary":"The Botanix Pharmaceuticals Ltd  share price is having a day to forget on Monday. In afternoon trade, the ASX 300 stock is down 18% to 38.2 cents. Why is this ASX 300 stock crashing?Despite today's decline, the Botanix share price is outperforming the benchmark index on a 12-month basis with an improved 38% gain.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/05/12/why-is-this-asx-300-stock-crashing-18-today-2/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7508","BK7096","BOT.AU","BK7502"],"gpt_icon":0},{"id":"2534262863","title":"Botanix Says Unlikely to be Impacted by Proposed US Drug Pricing Policy Order","url":"https://stock-news.laohu8.com/highlight/detail?id=2534262863","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534262863?lang=en_us&edition=fundamental","pubTime":"2025-05-12 11:43","pubTimestamp":1747021418,"startTime":"0","endTime":"0","summary":"Botanix Pharmaceuticals  said it is unlikely to be affected by a proposed US executive order that would tie US drug prices to the lowest price paid by any other country globally, according to a Monday filing with the Australian bourse.The company confirmed that its topical gel to treat excessive underarm sweating, Sofdra, is marketed exclusively in the US and is not sold in any other countries, the filing said.Botanix added that it will review the proposed order when available.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","BOT.AU","BK7502","BK7508"],"gpt_icon":0},{"id":"2527048658","title":"ASX Midday Sector Update: Healthcare Sector Jumps, Information Technology Stocks Struggle","url":"https://stock-news.laohu8.com/highlight/detail?id=2527048658","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527048658?lang=en_us&edition=fundamental","pubTime":"2025-04-15 11:36","pubTimestamp":1744688210,"startTime":"0","endTime":"0","summary":"The healthcare sector climbed 1.11% at midday Tuesday.Stocks rallied after some volatility on Wall Street, with investors cautiously optimistic after a temporary pause on tariffs on some electronic devices. The S&P 500 closed up 2.2%.Botanix Pharmaceuticals  received firm commitments to raise AU$40 million via a non-underwritten institutional placement, its shares rose 9% in midday trade.On the flip side, the information technology stocks fell, shedding 0.45%.EROAD  does not expect any material impact of the US' 10% blanket tariffs on its revenue or earnings, generating 44% of its revenue from the US market, with roughly 88% being from services not subject to the US import tariffs. It produces most of its hardware products through manufacturers in Indonesia, the Philippines, and Vietnam.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BOQ.AU","BK4134","ERD.AU","BK7096","III","BK7084","BK4137","BOT.AU","BK7139","HCSG","BK7502","BK7508"],"gpt_icon":0},{"id":"2527110765","title":"Botanix Pharmaceuticals Seeks AU$40 Million via Institutional Placement; Shares Rise 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2527110765","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527110765?lang=en_us&edition=fundamental","pubTime":"2025-04-15 10:56","pubTimestamp":1744685780,"startTime":"0","endTime":"0","summary":"Botanix Pharmaceuticals (ASX:BOT) received firm commitments to raise AU$40 million via a non-underwritten institutional placement, according to a Tuesday filing with the Australian bourse.The placemen","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7096","BOT.AU","BK7502"],"gpt_icon":0},{"id":"2527778741","title":"BRIEF-Botanix Pharmaceuticals Says Received Firm Commitments For A$40 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2527778741","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527778741?lang=en_us&edition=fundamental","pubTime":"2025-04-15 09:24","pubTimestamp":1744680299,"startTime":"0","endTime":"0","summary":"BRIEF-Botanix Pharmaceuticals Says Received Firm Commitments For A$40 Million April 15 (Reuters) - Botanix Pharmaceuticals BOT.AX:RECEIVED FIRM COMMITMENTS FOR A$40 MILLION CAPITAL RAISING AT ISSUE PRICE OF A$0.33 PER SHAREFurther company coverage: BOT.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nFWN3QS1Z6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","BK7508","BK7502","BOT.AU"],"gpt_icon":0},{"id":"2527916812","title":"BRIEF-Botanix Pharmaceuticals Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2527916812","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527916812?lang=en_us&edition=fundamental","pubTime":"2025-04-14 07:41","pubTimestamp":1744587700,"startTime":"0","endTime":"0","summary":"BRIEF-Botanix Pharmaceuticals Seeks Trading HaltApril 14 (Reuters) - Botanix Pharmaceuticals Ltd BOT.AX:SEEKS TRADING HALT PENDING ANNOUNCEMENT ON CAPITAL RAISINGFurther company coverage: BOT.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250413:nFWN3QQ05X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7096","BOT.AU","BK7502"],"gpt_icon":0},{"id":"2524179651","title":"3 reasons to buy this surging ASX All Ords healthcare share today","url":"https://stock-news.laohu8.com/highlight/detail?id=2524179651","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524179651?lang=en_us&edition=fundamental","pubTime":"2025-04-02 08:16","pubTimestamp":1743553014,"startTime":"0","endTime":"0","summary":"On 11 March, the ASX All Ords healthcare share held a commercial update conference. The company reported that there are 10 million people in the US with axillary hyperhidrosis, with 3.7 million of those people currently seeking treatment. Botanix said it will focus on those patients seeking treatment with its targeted sales force. But the company also aims to capture some of the 6.3 million patients not actively seeking treatment via digital messaging. Botanix shares could also catch some tailwinds from the stock's 24 March addition to the S&P/ASX 300 Index . That came as part of the S&P Dow Jones Indices quarterly review and followed the big increase in the company's market cap over the prior year. With the ASX All Ords healthcare share now also an ASX 300 stock, it opens the door for more fund managers and index tracking funds to buy the stock.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/02/3-reasons-to-buy-this-surging-asx-all-ords-healthcare-share-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7096","BK7508","BK7502","XAO.AU","BOT.AU","XKO.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":30,"code":"91000000","status":"200"}]}}